糖皮质激素与免疫检查点抑制剂在胶质母细胞瘤中的应用
本文探讨免疫检查点抑制剂激活T淋巴细胞而糖皮质激素损害其功能的机制,回顾免疫检查点抑制剂在胶质母细胞瘤中的临床数据及糖皮质激素对疗效的影响,并指出该领域尚存的关键问题及进一步研究中枢神经系统肿瘤的潜在获益。
要点
- 免疫检查点抑制剂在胶质母细胞瘤中的获益仍待观察,近期多项临床试验未显示疗效。
- 糖皮质激素可能损害免疫检查点抑制剂激发应答的能力,引发对其影响的担忧。
- 需更多关于糖皮质激素对接受PD-(L)1治疗患者的程度、特征和持续时间的信息。
核心结论
- 更多关于糖皮质激素对接受PD-(L)1治疗患者的程度、特征和持续时间的信息,将更好地指导中枢神经系统恶性肿瘤患者的临床管理和免疫治疗的新药开发。
研究设计与样本
- 本文为综述,检查了免疫检查点抑制剂激活T淋巴细胞及糖皮质激素损害T淋巴细胞功能的机制,并回顾免疫检查点抑制剂在胶质母细胞瘤中的临床数据及糖皮质激素对免疫检查点抑制剂疗效的影响。
主要发现
- 免疫检查点抑制剂在多种恶性肿瘤中已显示生存改善,但在胶质母细胞瘤中的获益仍待观察。
- 近期多项临床试验未能显示免疫治疗在胶质母细胞瘤中的疗效。
- 已引发对糖皮质激素使用可能损害免疫检查点抑制剂激发应答能力的担忧。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy, activation of the immune system to target tumor cells, represents a paradigm shift in the treatment of cancer. Immune checkpoint therapies, which target immunomodulatory molecules expressed on T-lymphocytes, have demonstrated improved survival in a variety of malignancies. However, benefit in glioblastoma, the most common and devastating malignant brain tumor, remains to be seen. With several recent clinical trials failing to show efficacy of immunotherapy, concerns have been raised regarding the impact of glucocorticoid use in this patient population that may impair the ability for immune checkpoint inhibitors to affect a response. METHODS: For this article we examined the mechanism by which immune checkpoint inhibitors activate, and glucocorticoids impair, T-lymphocyte function. RESULTS: In this context, we review the clinical data of immune checkpoint inhibitors in glioblastoma as well as the impact glucocorticoids have on immune checkpoint inhibitor efficacy. Finally, we highlight key questions that remain in the field, and the potential benefit of further research for central nervous system tumors. CONCLUSION: More information on the extent, character and duration of glucocorticoids on patients treated with PD-(L)1 will better inform both clinical management and novel therapeutic development of immunotherapy in patients with CNS malignancies.
引用
- Kelly WJ, Gilbert MR. Glucocorticoids and immune checkpoint inhibitors in glioblastoma. J Neurooncol. 2020. PMID: 32108294. doi:10.1007/s11060-020-03439-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。